Printer Friendly

UPJOHN ANNOUNCES NEW CONTRACEPTIVE OPTION AVAILABLE FOR U.S. WOMEN

 UPJOHN ANNOUNCES NEW CONTRACEPTIVE OPTION AVAILABLE FOR U.S. WOMEN
 KALAMAZOO, Mich., Oct. 29 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) announced today that Depo-Provera Contraceptive Injection has been cleared for marketing as a newly available birth control method for women in the U.S.
 Depo-Provera Contraceptive Injection is a prescription medication which contains the active ingredient medroxyprogesterone acetate, a synthetic form of the natural hormone progesterone. Each injection provides contraceptive protection for a three-month period.
 "Women around the world have found Depo-Provera to be a safe and reliable form of birth control," said Theodore Cooper, M.D., chairman and chief executive officer of The Upjohn Company. "We are pleased to provide Depo-Provera as another contraceptive option for women in the U.S."
 Depo-Provera is available for contraception in more than 90 countries, including Germany, Norway, Sweden, Belgium, France, the United Kingdom and New Zealand. It has been used by millions of women around the world since 1969.
 In studies, Depo-Provera is more than 99 percent effective, making it one of the most reliable birth control methods available. The effectiveness of Depo-Provera is dependent on the patient returning every three months for re-injection, rather than on daily compliance as with some other methods. The newly available contraceptive works in the same way as do other hormonal contraceptives such as the pill. When the brain perceives an increase in progestin levels following injection of Depo-Provera, it will suppress release of gonadotropic hormones that stimulate maturation and release of a mature egg. Without release of a mature egg, fertilization and pregnancy cannot occur.
 The most common side effects reported by women using Depo-Provera are changes in the menstrual cycle. These changes mostly consist of irregular or unpredictable bleeding or spotting. This tends to diminish and disappear after several injections. After one year of use, up to 50 percent of women will actually stop having their menstrual periods completely. However, when the injections are discontinued, normal menstruation will begin again.
 Other commonly reported side effects in clinical studies, which may be related to Depo-Provera, include weight gain, headache, nervousness, abdominal pain, dizziness and fatigue.
 In long-term WHO-sponsored studies of Depo-Provera users, results showed slight or no increased overall risk of breast cancer, no overall increased risk of ovarian, liver or cervical cancer and a prolonged, protective effect of reducing the risk of endometrial cancer in the population of users. Use of Depo-Provera is associated with a decrease in bone density and may be considered among the risk factors for osteoporosis.
 Like all hormonal contraceptives, Depo-Provera Contraceptive Injection should not be prescribed for pregnant women, women with undiagnosed vaginal bleeding, cancer of the breast, liver disease, blood clotting disorders or cerebral vascular disease. Women who are nursing should wait until the sixth week after giving birth before receiving an injection of Depo-Provera.
 Because Depo-Provera is a long-acting birth control method, it takes some time after the last injection for its effect to wear off. Studies have shown that women who discontinued Depo-Provera to become pregnant, and did become pregnant, conceived in 12-18 months following the last injection. (Most women not using any method of contraception will conceive in 12 months.) The length of time a woman receives Depo- Provera has no effect on how long it takes her to become pregnant.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 10/29/92
 /NOTE to TV Editors: Video B-Roll available. CONTACT: Florence Steinberg of The Upjohn Company, 616-323-7180/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU: PDT


JG -- DE018 -- 6597 10/29/92 12:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1992
Words:626
Previous Article:NEW HOTLINE OFFERS FRIENDS A CHANCE TO SEND ENCOURAGING 'WAKE UP' CALLS TO SMOKERS; CALLS PLACED ON THE DAY OF THE GREAT AMERICAN SMOKEOUT
Next Article:A.M. BEST PLACES CRUM AND FORSTER INSURANCE COMPANIES UNDER REVIEW
Topics:


Related Articles
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR UPJOHN CONTRACEPTIVE
UPJOHN ACQUIRES RIGHTS TO MARKET ESTROGEN REPLACEMENT DRUG OGEN FROM ABBOTT
UPJOHN: FDA ADVISORY COMMITTEE TABLES DISCUSSION ON UPJOHN INNOVATIVE DRUG FOR TREATMENT OF ANEURYSMAL SUBARACHNOID HEMORRHAGE
UPJOHN INCREASES AVAILABILITY OF DEPO-PROVERA TO TITLE X CLINICS
WYETH-AYERST JOINS ACOG IN CELEBRATING 35TH ANNIVERSARY OF 'THE PILL'
ADVISORY COMMITTEE RECOMMENDS APPROVAL OF CAMPTOSAR(TM) INJECTION
Pharmacia & Upjohn Introduces Estring for Postmenopausal Urogenital Symptoms
MIRCETTE(TM), Newest Low-Dose Oral Contraceptive, Now Available For Prescription
Pharmacia & Upjohn Receives FDA Approval for Aromasin in Advanced Breast Cancer and Submits New Drug Applications for New Antibiotic Zyvox.
The contraceptive conundrum.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters